The prognostic significance of early treatment response in pediatric relapsed acute myeloid leukemia: Results of the international study relapsed AML 2001/01

Haematologica

Volumn 99, Issue 9, 2014, Pages 1472-1478

  Creutzig, Ursula ^a   Zimmermann, Martin ^a   Dworzak, Michael N ^b   Gibson, Brenda ^c   Tamminga, Rienk ^d,e   Abrahamsson, Jonas ^f   Ha, Shau Yin ^g   Hasle, Henrik ^h   Maschan, Alexey ⁱ   Bertrand, Yves ^j   Leverger, Guy ^k   von Neuhoff, Christine ^a   Razzouk, Bassem ^l,m   Rizzari, Carmelo ⁿ   Smisek, Petr ^o   Smith, Owen P ^p   Stark, Batia ^q   Reinhardt, Dirk ^a   Kaspers, Gertjan L ^e,r  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^d UNIVERSITY OF GRONINGEN   (Netherlands)

^e DUTCH CHILDHOOD ONCOLOGY GROUP   (Netherlands)

^f QUEEN SILVIA CHILDREN'S HOSPITAL   (Sweden)

^g QUEEN MARY HOSPITAL   (Hong Kong)

^h AARHUS UNIVERSITY HOSPITAL   (Denmark)

ⁱ Center for Pediatric Hematology Oncology and Immunology   (Russian Federation)

^j FRALLE CLCG Institut d'Hématologie et d'Oncologie Pédiatrique   (France)

^k ARMAND TROUSSEAU HOSPITAL   (France)

^l ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^m Peyton Manning Children's Hospital   (United States)

ⁿ SAN GERARDO HOSPITAL   (Italy)

^o UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^p OUR LADY S CHILDREN S HOSPITAL   (Ireland)

^q SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^r VU UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; TIOGUANINE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BLAST CELL; CHILD; CLINICAL TRIAL; CYTOGENETICS; FEMALE; HUMAN; IMMUNOPHENOTYPING; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MORPHOLOGY; OVERALL SURVIVAL; PEDIATRIC RELAPSED ACUTE MYELOID LEUKEMIA; PROGNOSIS; TREATMENT RESPONSE; ADOLESCENT; BONE MARROW CELL; CONTROLLED STUDY; DRUG EFFECTS; DRUG MONITORING; LEUKEMIA, MYELOID, ACUTE; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REMISSION; SURVIVAL;

ADOLESCENT; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW CELLS; CHILD; CHILD, PRESCHOOL; DAUNORUBICIN; DRUG MONITORING; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; PROGNOSIS; RECURRENCE; REMISSION INDUCTION; SURVIVAL ANALYSIS;

EID: 84906071153     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.104182     Document Type: Article

References (18)

1. Goemans BF, Tamminga RY, Corbijn CM, Hahlen K, Kaspers GJ. Outcome for children with relapsed acute myeloid leukemia in the Netherlands following initial treatment between 1980 and 1998: survival after chemotherapy only? Haematologica 2008;93(9):1418-20.
2. Gorman MF, Ji L, Ko RH, Barnette P, Bostrom B, Hutchinson R, et al. Outcome for children treated for relapsed or refractory acute myelogenous leukemia (rAML): a Therapeutic Advances in Childhood Leukemia (TACL) Consortium study. Pediatr Blood Cancer. 2010;55(3):421-9.
3. Abrahamsson J, Clausen N, Gustafsson G, Hovi L, Jonmundsson G, Zeller B, et al. Improved outcome after relapse in children with acute myeloid leukaemia. Br J Haematol. 2007;136(2):229-36.
4. Aladjidi N, Auvrignon A, Leblanc T, Perel Y, Benard A, Bordigoni P, et al. Outcome in children with relapsed acute myeloid leukemia after initial treatment with the French Leucemie Aique Myeloide Enfant (LAME) 89/91 protocol of the French Society of Pediatric Hematology and Immunology. J Clin Oncol. 2003;21(23): 4377-85.
5. Rubnitz JE, Razzouk BI, Lensing S, Pounds S, Pui CH, Ribeiro RC. Prognostic factors and outcome of recurrence in childhood acute myeloid leukemia. Cancer. 2007; 109(1):157-63.
6. Sander A, Zimmermann M, Dworzak M, Fleischhack G, von Neuhoff C, Reinhardt D et al. Consequent and intensified relapse therapy improved survival in pediatric AML: results of relapse treatment in 379 patients of three consecutive AML-BFM trials. Leukemia. 2010; 24(8):1422-8.
7. Webb DK, Wheatley K, Harrison G, Stevens R F, Hann IM. Outcome for children with relapsed acute myeloid leukaemia following initial therapy in the Medical Research Council (MRC) AML 10 trial. MRC Childhood Leukaemia Working Party. Leukemia. 1999;13(1):25-31.
8. Kaspers GJ, Zimmermann M, Reinhardt D, Gibson BE, Tamminga RY, Aleinikova O, et al. Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group. J Clin Oncol. 2013;31(5):599-607.
9. Kaspers GJ. Pediatric acute myeloid leukemia. Expert Rev Anticancer Ther. 2012; 12(3):405-13.
10. Stahnke K, Boos J, Bender-Gotze C, Ritter J, Zimmermann M, Creutzig U. Duration of first remission predicts remission rates and long-term survival in children with relapsed acute myelogenous leukemia. Leukemia. 1998;12(10):1534-38.
11. Creutzig U, Zimmermann M, Ritter J, Henze G, Graf N, Loffler H, et al. Definition of a standard-risk group in children with AML. Br J Haematol. 1999; 104(3):630-9.
12. Langebrake C, Creutzig U, Dworzak M, Hrusak O, Mejstrikova E, Griesinger F, et al. Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group. J Clin Oncol. 2006;24(22): 3686-92.
13. Kern W, Haferlach T, Schoch C, Loffler H, Gassmann W, Heinecke A, et al. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial. Blood. 2003;101(1):64-70.
14. Inaba H, Coustan-Smith E, Cao X, Pounds SB, Shurtleff SA, Wang KY, et al. Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia. J Clin Oncol. 2012;30 (29):3625-32.
15. Loken MR, Alonzo TA, Pardo L, Gerbing RB, Raimondi SC, Hirsch BA et al. Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group. Blood. 2012;120(8):1581-8.
16. Rubnitz JE, Inaba H, Dahl G, Ribeiro RC, Bowman W P, Taub J, et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol. 2010;11(6): 543-52.
17. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21 (24):4642-9.
18. Creutzig U, van den Heuvel-Eibrink MM, Gibson B, Dworzak MN, Adachi S, de Bont E, et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood. 2012;120(16): 3187-205.